Understanding Pemphigus Foliaceus: A Guide to Your Diagnosis
At a Glance
Pemphigus foliaceus is a rare autoimmune disease where the immune system attacks the skin, causing red, scaly, and crusty patches. Unlike other forms of pemphigus, it rarely affects the mouth or eyes. It is highly treatable with medications like corticosteroids and rituximab to achieve remission.
Finding out you have a rare disease like Pemphigus Foliaceus (PF) can feel like your world has been turned upside down. It is natural to feel overwhelmed or even frightened by the medical terminology and the changes in your skin. However, PF is a well-studied condition with clear management strategies.
At its core, PF is a rare autoimmune disease, meaning your immune system—which normally protects you from germs—has mistakenly started attacking a protein in your skin called desmoglein-1 [1][2]. This protein acts like the “glue” that holds your skin cells together. When it is attacked, the cells in the very top layer of your skin separate, leading to the scaling and crusting that you may be seeing [3].
Three Facts to Help You Breathe Easier
When you are first diagnosed, it is easy to focus on the worst-case scenarios. Here are three stabilizing facts to help ground your perspective:
- Your mouth and eyes are safe: Unlike other forms of pemphigus, PF almost never involves the mucous membranes, such as the inside of your mouth, eyes, or genitals [4]. This is because your body has a “backup” protein in those areas that continues to hold your cells together even when desmoglein-1 is under attack.
- It is exceptionally rare: In the United States and Europe, PF affects only about 0.5 to 1 person per million every year [5]. You are not alone, but you are dealing with a condition that requires specialized care from a dermatologist who understands rare diseases.
- The prognosis is favorable: Compared to other types of pemphigus, PF generally has a better outlook, lower mortality rates, and may be less likely to come back once it is under control [6][7].
Understanding the Disease Path
PF is a chronic condition, which means it is a journey rather than a quick fix. However, “chronic” does not mean “uncontrolled.” The goal of treatment is to reach clinical remission—a state where your skin has healed and no new lesions are forming [8].
- Appearance: Because the separation happens so close to the surface, you may never see actual blisters. Instead, PF often looks like red, scaly, or “crusty” patches that can be mistaken for other conditions like seborrheic dermatitis or impetigo [3][9].
- Triggers: Many patients find that their skin is sensitive to ultraviolet (UV) light. Sun exposure can sometimes make the condition flare up, so protecting your skin from the sun is often a key part of management.
How PF is Managed
The way doctors treat PF has evolved. While high-dose corticosteroids (like prednisone) were once the only option, modern medicine offers more targeted approaches:
- Steroid-Sparing Agents: To avoid the long-term side effects of steroids, doctors often use other medications like azathioprine or mycophenolate mofetil to help keep the immune system in check [8][10].
- Biological Therapy: A treatment called rituximab is now frequently used as a first-line therapy for moderate to severe cases [11]. It works by targeting the specific immune cells that produce the harmful antibodies, often allowing patients to reduce their steroid use more quickly [12].
- Consistency is Key: Adhering to your medication schedule is the most important factor in reaching and staying in remission [13]. Your care team will monitor you closely to adjust your doses based on how your skin and your blood tests respond [14].
You are entering a phase of management and healing. While the diagnosis is serious, PF is a manageable condition, and with the right care team, most patients lead full, active lives.
Common questions in this guide
What does pemphigus foliaceus look like?
Will pemphigus foliaceus affect the inside of my mouth or eyes?
How is pemphigus foliaceus treated?
Can sun exposure make my skin worse?
What is anti-desmoglein-1?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific tests (like biopsy or ELISA) confirmed my diagnosis of Pemphigus Foliaceus?
- 2.How do you plan to monitor my antibody levels (anti-desmoglein-1) to track my treatment progress?
- 3.Based on my severity, should we consider rituximab as a first-line treatment instead of high-dose steroids?
- 4.Are there specific signs of infection I should watch for while on immunosuppressants?
- 5.How will we manage potential side effects of my medications over the long term?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Role of Dsg1- and Dsg3-Mediated Signaling in Pemphigus Autoantibody-Induced Loss of Keratinocyte Cohesion.
Walter E, Vielmuth F, Wanuske MT, et al.
Frontiers in immunology 2019; (10()):1128 doi:10.3389/fimmu.2019.01128.
PMID: 31178865 - 2
Differentiating Pemphigus Foliaceus From Pemphigus Vulgaris in Clinical Practice.
Stumpf N, Huang S, Hall LD, Hsu S
Cureus 2021; (13(9)):e17889 doi:10.7759/cureus.17889.
PMID: 34548989 - 3
Red crusty plaques in a young man.
Farsi M, Johnson CM, Segars K, Rhim J
Dermatology online journal 2023; (29(5)) doi:10.5070/D329562411.
PMID: 38478647 - 4
Eye and lid involvement as an uncommon feature of pemphigus foliaceus in a pediatric patient.
Garza-Dávila VF, Santana-Gutiérrez A, Zapata-Salazar N, et al.
Pediatric dermatology 2024; (41(5)):853-856 doi:10.1111/pde.15594.
PMID: 38459607 - 5
Incidence of pemphigus vulgaris and pemphigus foliaceus in North-East Poland (Podlaskie Province) - a 15-year (2001-2015) bicentric retrospective study.
Serwin AB, Koper M, Flisiak I
International journal of dermatology 2018; (57(8)):933-937 doi:10.1111/ijd.14078.
PMID: 29873080 - 6
Pemphigus Vulgaris and Pemphigus Foliaceus: Differences in Epidemiology and Mortality.
Kridin K, Zelber-Sagi S, Bergman R
Acta dermato-venereologica 2017; (97(9)):1095-1099 doi:10.2340/00015555-2706.
PMID: 28536732 - 7
Pemphigus subtype: a confounder in determining the association of oral involvement with post-rituximab relapses.
Kneiber D, Kowalski EH, Kridin K, Amber KT
Dermatologic therapy 2019; (32(3)):e12918 doi:10.1111/dth.12918.
PMID: 30977210 - 8
Epidemiology and Factors Associated with Remission of Pemphigus Vulgaris and Foliaceus in Singapore.
Cai SC, Zhao X, Tang MB, Lim YL
Annals of the Academy of Medicine, Singapore 2020; (49(6)):367-376.
PMID: 32712634 - 9
Atypical pemphigus foliaceus with pustular lesions: a case series.
Pangastuti M, Sundani A, Suwarsa O, et al.
Journal of medical case reports 2026; (20(1)).
PMID: 42343341 - 10
Clinicodemographic characteristics of pemphigus foliaceus: retrospective analysis of clinic-based data for 103 patients in a nonendemic location.
De D, Sharma A, Hanumanthu V, et al.
Clinical and experimental dermatology 2026; (51(5)):840-845 doi:10.1093/ced/llaf408.
PMID: 40931562 - 11
Ocrelizumab, an alternative to rituximab in refractory pemphigus vulgaris management.
de-la-Rosa-Fernández E, Loizate-Sarrionandia I, González-Rodríguez J, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2023; (37(9)):e1104-e1106 doi:10.1111/jdv.19133.
PMID: 37102356 - 12
Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis.
Kieffer C, Hebert V, Joly P, Tedbirt B
Dermatology and therapy 2026; doi:10.1007/s13555-026-01811-0.
PMID: 42390708 - 13
A Case of Recurrent Pemphigus Foliaceus Following Noncompliance to Medication.
Ali M, Ahmad MH, Imran A, et al.
Clinical case reports 2024; (12(11)):e9622 doi:10.1002/ccr3.9622.
PMID: 39582723 - 14
Feline pemphigus foliaceus in non-specialist veterinary practice: a retrospective analysis.
Coyner K, Tater K, Rishniw M
The Journal of small animal practice 2018; (59(9)):553-559 doi:10.1111/jsap.12869.
PMID: 29961990
This page is for informational purposes only and does not replace professional medical advice. Always consult your dermatologist about your specific pemphigus foliaceus diagnosis and treatment plan.
Get notified when new evidence is published on Pemphigus foliaceus.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.